Elevated Triglycerides: PSC vs PBC
Elevated triglycerides are NOT characteristically associated with either PSC or PBC, but when present, they are slightly more common in PSC than PBC, particularly in advanced disease stages.
Lipid Profile Distinctions
Primary Sclerosing Cholangitis (PSC)
PSC typically presents with hypercholesterolemia rather than hypertriglyceridemia. The lipid abnormalities include:
- Total cholesterol elevation is the predominant finding, occurring in 41% of early-stage patients and 29% of pretransplant patients 1
- Triglyceride elevation is uncommon: Only 2% of early PSC patients and 17% of pretransplant patients show elevated triglycerides 1
- When triglycerides are elevated, median levels remain relatively modest at 102 mg/dL (range 41-698) 2
- HDL cholesterol is often elevated (20% above normal), which is atypical for most dyslipidemic conditions 1
The cholesterol elevation in PSC correlates with disease severity—total cholesterol levels increase with higher serum bilirubin and more advanced histologic stages 1, 2.
Primary Biliary Cholangitis (PBC)
PBC demonstrates a distinctive hypercholesterolemic profile with paradoxically high HDL 3:
- Marked elevation in total cholesterol is the hallmark finding
- The cholesterol increase is primarily due to lipoprotein X (LP-X), an abnormal LDL particle with anti-atherogenic properties 4
- Triglycerides are not a characteristic feature of PBC's lipid profile
- The dyslipidemia affects most lipoprotein classes but is dominated by cholesterol abnormalities 4
Key Clinical Distinctions
Important caveat: Despite significant hypercholesterolemia in both conditions, neither PSC nor PBC appears to confer increased cardiovascular risk. PSC patients show only 4% incidence of coronary artery disease 2, and PBC demonstrates no robust evidence of increased cardiac atherosclerotic risk 5, 4.
Metabolomic Differences
Recent metabolomic profiling identified 56 metabolites that differ significantly between PSC and PBC, with protein and amino acid metabolism being the major distinguishing factors rather than triglyceride metabolism 6.
Clinical Implications
- Screen for fat-soluble vitamin deficiencies in both conditions, especially with advanced disease (82% vitamin A deficiency, 57% vitamin D deficiency in advanced PSC) 1
- Lipid-lowering therapy decisions should be based on overall cardiovascular risk factors rather than the cholestatic disease itself, as the elevated lipids in both conditions do not appear to increase atherosclerotic risk 5, 4
- Differential cholesterol assessment is necessary in PBC due to HDL hypercholesterolemia 5
The bottom line: triglyceride elevation is not a defining feature of either condition, but when present, it occurs slightly more frequently in advanced PSC (17%) compared to its rarity in PBC.